(Q37282300)

19 August 2017

1 reference

title

Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease (English)

1 reference

19 August 2017

0 references

cardiovascular disease

1 reference

Jessica Kendrick

1

1 reference

PubMed ID

18825155

19 August 2017

Michel B Chonchol

series ordinal

2

1 reference

19 August 2017

30 September 2008

1 reference

Nature Clinical Practice Nephrology

19 August 2017

1 reference

19 August 2017

4

1 reference

19 August 2017

672-681

1 reference

19 August 2017

12

1 reference

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

19 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

21 January 2018

Leptin and renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

Beta blockers in the management of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Prevalence of chronic kidney disease in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Traditional and nontraditional cardiovascular risk factors in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Mild renal insufficiency is associated with angiographic coronary artery disease in women

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Beyond (or back to) traditional risk factors: preventing cardiovascular disease in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Low-grade inflammation and microalbuminuria in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Microalbuminuria and endothelial dysfunction in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Microalbuminuria and early endothelial activation in essential hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Relationship between albuminuria and cardiovascular disease in Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Anemia: an early complication of chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Antioxidants and atherosclerotic heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Modulation of the inflammatory response in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Kidney function as a predictor of noncardiovascular mortality

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

The effect of reduced glomerular filtration rate on plasma total homocysteine concentration

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Homocysteine lowering and cardiovascular events after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Homocysteine lowering with folic acid and B vitamins in vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Serum phosphate levels and mortality risk among people with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Death risk factor analysis in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Parathyroid hormone and left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Arterial stiffening and vascular calcifications in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Current role of beta-adrenergic blockers in the management of chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Beta-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0954

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0954

1 reference

19 August 2017

1 reference

PubMed ID

18825155